InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Shah Preetam, Chief Financial Officer. Director active across 1 companies, notably Cidara Therapeutics, Inc.. In total, 3 reports have been published. Total volume traded: €54k. The latest transaction was disclosed on 31 March 2022 — Attribution. Regulator: SEC (Form 4). The full history is openly available.
Declarations3 total
051,250 shares0
Common Stock
SEC:0001610618-22-000029:0·
€26,89820,000 shares@ €1.3449100.0% of flow
Common Stock
SEC:0001610618-21-000106·
Ideal exit: 9 Aug 2022 (T+270)
€26,89820,000 shares@ €1.344950.0% of flow
Common Stock
SEC:0001610618-21-000106:0·
Ideal exit: 9 Aug 2022 (T+270)
3 of 3 declarations
About Shah Preetam
Preetam Shah serves as Chief Financial Officer and Chief Business Officer at Cidara Therapeutics, Inc. In this role, he oversees the financial and business functions of the company. Cidara Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative treatments. Shah plays a key role in financial and business strategy, thereby contributing to the company's growth and sustainability.
